Introduction & Objectives: A prior multinational study showed improved time in range (TIR; 70-180 mg/dL) in people living with type 1 or type 2 diabetes (PLWD) after smart pen initiation for their bolus insulin. To understand country-specific experiences with smart pen use, this study replicated the analysis, focusing on PLWD in Austria.
Methods: Real-world data (RWD) were collected from adults in Austria on a multiple daily insulin regimen who were already using a continuous glucose monitoring (CGM) device and initiating a smart pen. Days were included if an individual had ≥1 data upload (pen to app) within the last 14 days and ≥15% time covered by CGM sensor readings. Key glycemic outcomes were TIR and time below range (TBR; <3.9 mmol/L).
Results: Data from 1336 adults (mean 49.1 years) were analyzed (101 394 days with CGM data and recorded bolus injections). Mean TIR increased by 4.0% at month 3 (95% CI 3.0, 5.1; p < 0.001) and was sustained at month 6 (95% CI 2.7, 5.2; p < 0.001) (Figure). TBR decreased significantly from baseline by month 3, but was not statistically significant at month 6. The percentage of participants with TIR >70% increased from 35% at baseline to 42% at 6 months (p < 0.001).
Conclusion: RWD from Austria shows a clear glycemic improvement after smart pen initiation. Analyzing country-specific experiences is important to understand the potential impact of smart pen use and how PLWD and physicians can most benefit from this technology.
J.K. Mader: Advisory Panel; Becton, Dickinson and Company. Speaker's Bureau; Becton, Dickinson and Company, A. Menarini Diagnostics, Boehringer-Ingelheim, diaTribe. Other Relationship; Diabetes UK. Stock/Shareholder; decide Clinical Software GmbH. Advisory Panel; embecta. Speaker's Bureau; embecta, Viatris Inc., Eli Lilly and Company. Advisory Panel; Eli Lilly and Company, Medtronic. Speaker's Bureau; Medtrust. Advisory Panel; Novo Nordisk A/S. Speaker's Bureau; Novo Nordisk A/S. Advisory Panel; PharmaSens, Roche Diabetes Care. Speaker's Bureau; Roche Diabetes Care. Board Member; Sanofi-Aventis Deutschland GmbH. Speaker's Bureau; Sanofi-Aventis Deutschland GmbH, Sanofi, Dexcom, Inc., Viatris Inc. Advisory Panel; Viatris Inc. Speaker's Bureau; Ypsomed AG. Research Support; European Union. Stock/Shareholder; elyte Diagnostics GmbH. Other Relationship; elyte Diagnostics GmbH. Board Member; European Association for the Study of Diabetes. Research Support; European Union Aviation Safety Agency. N.V. Hartvig: Stock/Shareholder; Novo Nordisk A/S. Employee; Novo Nordisk A/S. A. Kaas: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. N.N. Knudsen: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. Y. Winhofer: None.
Novo Nordisk A/S
